D. Mark Hickinson

639 total citations
14 papers, 501 citations indexed

About

D. Mark Hickinson is a scholar working on Oncology, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, D. Mark Hickinson has authored 14 papers receiving a total of 501 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Oncology, 7 papers in Molecular Biology and 7 papers in Pulmonary and Respiratory Medicine. Recurrent topics in D. Mark Hickinson's work include HER2/EGFR in Cancer Research (7 papers), Lung Cancer Treatments and Mutations (7 papers) and Colorectal Cancer Treatments and Studies (4 papers). D. Mark Hickinson is often cited by papers focused on HER2/EGFR in Cancer Research (7 papers), Lung Cancer Treatments and Mutations (7 papers) and Colorectal Cancer Treatments and Studies (4 papers). D. Mark Hickinson collaborates with scholars based in United Kingdom, France and United States. D. Mark Hickinson's co-authors include Robert W. Wilkinson, Laurent Hennequin, Donald Ogilvie, Barry R. Davies, Teresa Klinowska, Judith Anderton, Georgina Speake, Gayle Marshall, Tim P. Green and Bernard Barlaam and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and Current Biology.

In The Last Decade

D. Mark Hickinson

14 papers receiving 488 citations

Peers

Countries citing papers authored by D. Mark Hickinson

Since Specialization

Citations

This map shows the geographic impact of D. Mark Hickinson's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by D. Mark Hickinson with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites D. Mark Hickinson more than expected).

Fields of papers citing papers by D. Mark Hickinson

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by D. Mark Hickinson. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by D. Mark Hickinson. The network helps show where D. Mark Hickinson may publish in the future.

Co-authorship network of co-authors of D. Mark Hickinson

This figure shows the co-authorship network connecting the top 25 collaborators of D. Mark Hickinson. A scholar is included among the top collaborators of D. Mark Hickinson based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with D. Mark Hickinson. D. Mark Hickinson is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

14 of 14 papers shown

#	Work	Indexed citations
1	Discovery of AZD8931, an Equipotent, Reversible Inhibitor of Signaling by EGFR, HER2, and HER3 Receptors 2013 ·ACS Medicinal Chemistry Letters ·Bernard Barlaam, Judith Anderton, Peter Ballard, Robert H. Bradbury, Laurent Hennequin, D. Mark Hickinson, Jason G. Kettle, (unknown), Teresa Klinowska, Christine Lambert‐van der Brempt, Cath Trigwell, John P. Vincent, Donald Ogilvie	31
2	Src Family Kinase Inhibitor Saracatinib (AZD0530) Impairs Oxaliplatin Uptake in Colorectal Cancer Cells and Blocks Organic Cation Transporters 2010 ·Cancer Research ·Christopher J. Morrow, Mohammad A. Ghattas, Christopher G. Smith, Heinz Bönisch, Richard A. Bryce, D. Mark Hickinson, Tim P. Green, Caroline Dive	24
3	AZD8931, an Equipotent, Reversible Inhibitor of Signaling by Epidermal Growth Factor Receptor, ERBB2 (HER2), and ERBB3: A Unique Agent for Simultaneous ERBB Receptor Blockade in Cancer 2010 ·Clinical Cancer Research ·D. Mark Hickinson, Teresa Klinowska, Georgina Speake, John P. Vincent, Cath Trigwell, Judith Anderton, Sarah Beck, Gayle Marshall, Sara Davenport, Rowena Callis, Elizabeth Mills, Konstantina Grosios, Paul D. Smith, Bernard Barlaam, Robert W. Wilkinson, Donald Ogilvie	95
4	Identification of Biomarkers in Human Head and Neck Tumor Cell Lines That Predict For In Vitro Sensitivity to Gefitinib 2009 ·Clinical and Translational Science ·D. Mark Hickinson, Gayle Marshall, Garry Beran, Marileila Varella‐Garcia, Elizabeth Mills, (unknown), (unknown), (unknown), Gael McWalter, Rose McCormack, Paul A. Bunn, Tim French, (unknown), Brian R. Holloway, Fred R. Hirsch, Georgina Speake	17
5	Epidermal growth factor receptor tyrosine kinase inhibitors: similar but different? 2009 ·Anti-Cancer Drugs ·Yuri Rukazenkov, Georgina Speake, Gayle Marshall, Judith Anderton, Barry R. Davies, Robert W. Wilkinson, D. Mark Hickinson, Alan Swaisland	43
6	Preclinical anticancer activity of the potent, oral Src inhibitor AZD0530 2009 ·Molecular Oncology ·Tim P. Green, (unknown), (unknown), Jon Curwen, Vivien N. Jacobs, J M Allen, Armelle Logié, Judith Hargreaves, D. Mark Hickinson, Robert W. Wilkinson, Paul Elvin, Brigitte Boyer, Neil O. Carragher, Patrick A. Plé, Alun Bermingham, Geoffrey A. Holdgate, Walter H.J. Ward, Laurent Hennequin, Barry R. Davies, Gerard Costello	176
7	265 POSTER A MEK1/2 inhibitor, AZD6244 (ARRY-142886), shows beneficial effects when combined with standards of care or novel therapies – mechanistic characterisation suggests a role for apoptosis 2008 ·European Journal of Cancer Supplements ·Sarah V. Holt, Armelle Logié, Barry R. Davies, (unknown), (unknown), (unknown), D. Mark Hickinson, (unknown), Paul D. Smith, Robert W. Wilkinson	1
8	Neutral 5-substituted 4-anilinoquinazolines as potent, orally active inhibitors of erbB2 receptor tyrosine kinase 2007 ·Bioorganic & Medicinal Chemistry Letters ·Peter Ballard, Bernard Barlaam, Robert H. Bradbury, Allan Dishington, Laurent Hennequin, D. Mark Hickinson, (unknown), Jason G. Kettle, Teresa Klinowska, Donald Ogilvie, Stuart E. Pearson, James S. Scott, Abid Suleman, (unknown), Emma Williams, Robin Wood, (unknown)	23
9	A new series of neutral 5-substituted 4-anilinoquinazolines as potent, orally active inhibitors of erbB2 receptor tyrosine kinase 2007 ·Bioorganic & Medicinal Chemistry Letters ·Bernard Barlaam, Peter Ballard, Robert H. Bradbury, Richard Ducray, (unknown), D. Mark Hickinson, Kevin Hudson, Jason G. Kettle, Teresa Klinowska, (unknown), Donald Ogilvie, Annie Olivier, Stuart E. Pearson, James S. Scott, Abid Suleman, Cath Trigwell, (unknown), (unknown), Robin Wood	18
10	Role of EGFR but not HER2 or HER3 gene copy number in predicting sensitivity of head and neck squamous cell carcinoma (SCCHN) cell lines to EGFR tyrosine kinase inhibitors 2007 ·Journal of Clinical Oncology ·Marileila Varella‐Garcia, (unknown), Gayle Marshall, R. McCormack, Anderson J. Ryan, Fred R. Hirsch, Paul A. Bunn, D. Mark Hickinson, Georgina Speake	1
11	A pharmacological comparison of gefitinib (IRESSA) and erlotinib 2006 ·Georgina Speake, Gayle Marshall, Judith Anderton, (unknown), Armelle Logié, (unknown), R. McCormack, P H Smith, B. R. Holloway, Barry R. Davies, D. Mark Hickinson	2
12	5-Substituted 4-anilinoquinazolines as potent, selective and orally active inhibitors of erbB2 receptor tyrosine kinase 2005 ·Bioorganic & Medicinal Chemistry Letters ·Peter Ballard, Robert H. Bradbury, Laurent Hennequin, D. Mark Hickinson, Paul D. Johnson, Jason G. Kettle, Teresa Klinowska, Rémy Morgentin, Donald Ogilvie, Annie Olivier	31
13	Association of a phosphatidylinositol-specific 3-kinase with a human trans -Golgi network resident protein 1997 ·Current Biology ·D. Mark Hickinson, John M. Lucocq, Mhairi C. Towler, (unknown), Joanna L. James, Sarah James, C. Peter Downes, Sreenivasan Ponnambalam	24
14	Cross-talk between phospholipase C and phosphoinositide 3-kinase signalling pathways 1997 ·Biochemical Society Transactions ·Ian H. Batty, D. Mark Hickinson, (unknown)	15

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact